



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/149168/>

Version: Accepted Version

Article:

Battelino, T., Danne, T., Bergenstal, R.M. et al. (2019) Clinical targets for continuous glucose monitoring data interpretation : recommendations from the international consensus on time in range. *Diabetes Care*, 42 (8). pp. 1593-1603. ISSN: 0149-5992

<https://doi.org/10.2337/dci19-0028>

This is an author-created, uncopyedited electronic version of an article accepted for publication in *Diabetes Care*. The American Diabetes Association (ADA), publisher of *Diabetes Care*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version is available in *Diabetes Care* in print and online at <https://doi.org/10.2337/dci19-0028>.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

TITLE:

Clinical Targets for Continuous Glucose Monitoring Data Interpretation:
Recommendations from the International Consensus on Time-in-Range

RUNNING TITLE:

CGM Time-In-Range Consensus

AUTHORS:

Tadej Battelino, Department of Pediatric Endocrinology, Diabetes and Metabolism,
University Medical Centre-University Children's Hospital, and Faculty of Medicine,
University of Ljubljana, Slovenia

Thomas Danne, Diabetes Centre for Children and Adolescents, AUF DER BULT, Kinder-
und Jugendkrankenhaus, Hannover, Germany

Stephanie A. Amiel, Diabetes Research Group, King's College London, London, United
Kingdom

Roy Beck, Jaeb Center for Health Research, Tampa, Florida, USA

Richard M. Bergenstal, International Diabetes Center at Park Nicollet, Minneapolis, MN,
USA

Torben Biester, Diabetes Centre for Children and Adolescents, AUF DER BULT, Kinder-
und Jugendkrankenhaus, Hannover, Germany

Emanuele Bosi, Diabetes Research Institute, IRCCS San Raffaele Hospital, Vita-Salute San
Raffaele University, Milan, Italy.

Bruce Buckingham, Stanford Medical Center, Department of Pediatrics, Division of
Endocrinology and Diabetes, Stanford, CA, U.S.A

William Cefalu, American Diabetes Association, Alexandria, VA, USA

Kelly L. Close, Close Concerns and diaTribe, San Francisco, California, USA

Claudio Cobelli, Department of Information Engineering, University of Padova, Padova,
Italy.

Eyal Dassau, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA

J. Hans DeVries, Profil, Neuss, Germany and Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Kim Donaghue, The Children's Hospital at Westmead, University of Sydney, Australia,

Klemen Dovc, Department of Pediatric Endocrinology, Diabetes and Metabolism, University Medical Centre-University Children's Hospital, Ljubljana, Slovenia

Francis J. Doyle III, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA

Satish Garg, University of Colorado Denver and Barbara Davis Center for Diabetes, Aurora, Colorado USA

George Grunberger, Grunberger Diabetes Institute, Bloomfield Hills, Michigan, USA

Simon Heller, Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, United Kingdom

Lutz Heinemann, Science Consulting in Diabetes, Neuss, Germany

Irl B. Hirsch, Department of Medicine, Division of Metabolism, Endocrinology, & Nutrition, University of Washington School of Medicine, Seattle, Washington, USA

Roman Hovorka, Wellcome Trust-MRC Institute of Metabolic Science, and Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom

Weiping Jia, Department of Endocrinology & Metabolism, Shanghai Clinical Center of Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

Olga Kordonouri, Diabetes Centre for Children and Adolescents, AUF DER BULT, Kinder- und Jugendkrankenhaus, Hannover, Germany

Boris Kovatchev, Center for Diabetes Technology, University of Virginia, Charlottesville, VA, U.S.A

Aaron Kowalski, Juvenile Diabetes Research Foundation, New York, New York, USA

Lori Laffel, Pediatric, Adolescent and Young Adult Section and Section on Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Harvard Medical School, Boston, MA, U.S.A

Brian Levine, Close Concerns and diaTribe, San Francisco, California, USA

Aleksander Mayorov, I.M. Sechenov First Moscow State Medical University, Moscow,
Russia

Chantal Mathieu, MD, Clinical and Experimental Endocrinology, KU Leuven, Leuven,
Belgium

Helen R. Murphy, Norwich Medical School, University of East Anglia, Norwich, United
Kingdom

Revital Nimri, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes,
National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel,
Petah Tikva, and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

Kirsten Nørgaard, Steno Diabetes Center Copenhagen, Gentofte, Denmark

Christopher G. Parkin, CGParkin Communications, Inc., Boulder City, NV, USA

Eric Renard, Montpellier University Hospital, Department of Endocrinology, Diabetes,
Nutrition, Montpellier, and Institute of Functional Genomics, University of Montpellier,
Montpellier, and INSERM Clinical Investigation Centre, Montpellier, France.

David Rodbard, Biomedical Informatics Consultants LLC, Potomac, Maryland, USA

Banshi Saboo, DiaCare, Ahmedabad, Gujarat, India

Desmond Schatz, University of Florida, Pediatric Endocrinology, Gainesville, FL, USA

Keaton Stoner, dQ&A Market Research, Inc., San Francisco, California, USA

Tatsuiko Urakami, Department of Pediatrics, Nihon University School of Medicine, Tokyo,
Japan

Stuart A. Weinzimer, Department of Pediatrics, Yale School of Medicine, New Haven,
Connecticut, USA

Moshe Phillip, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes,
National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel,
Petah Tikva, and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

CORRESPONDING AUTHOR

Tadej Battelino, Department of Pediatric Endocrinology, Diabetes and Metabolism,
University Medical Centre-University Children's Hospital, and Faculty of Medicine,
University of Ljubljana, Slovenia, (+386 1 522 9235), tadej.battelino@mf.uni-lj.si

WORD COUNT

FIGURES / TABLES

2 Figures / 3 Tables

ABBREVIATIONS

A1C=glycated hemoglobin; AGP=ambulatory glucose profile; ATTD=Advanced Technologies & Treatments for Diabetes; AUC= area under the curve; CGM=continuous glucose monitoring; CI=confidence interval; DR=diabetic retinopathy; GMI=glucose management indicator; GV=glycemic variability; HBGI-high blood glucose index; HCL=hybrid closed-loop; iCGM=intermittently-scanned continuous glucose monitoring; MDI=multiple daily injections; NPDR=mild nonproliferative diabetic retinopathy; rtCGM=real-time continuous glucose monitoring; LBGI-low blood glucose index; SD=standard deviation; SGLT-2=sodium glucose cotransporter-2; TAR=time above range; TBR=time below range; TIR=time in range; VTDR=vision-threatening diabetic retinopathy

(ABSTRACT)

Improvements in sensor accuracy, greater convenience and ease of use and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed upon glycemic targets that both diabetes teams and people with diabetes can work towards. Although unified recommendations for use of key CGM metrics have been established in three separate peer reviewed articles, formal adoption by diabetes professional organizations, and guidance in the practical application of these metrics in clinical practice has been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

Adoption of continuous glucose monitoring (CGM), which includes both real-time CGM (rtCGM) and intermittently-scanned CGM (isCGM), has grown rapidly over the past few years due to improvements in sensor accuracy, greater convenience and ease of use and expanding reimbursement. Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15). In many countries, the benefits and utility of CGM are now recognized by national and international medical organizations for individuals with insulin-requiring diabetes and/or those at risk for hypoglycemia (16-21). However, despite increased CGM adoption (22; 23), successful utilization of CGM data in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed upon glycemic targets toward which both diabetes teams and people with diabetes can work.

In 2012 the Helmsley Charitable Trust sponsored the first expert panel to recommend the standardization of CGM metrics and CGM report visualization (24). This was followed by a series of CGM consensus statements refining the core CGM metrics but the conclusions were never in alignment. In 2017, several articles supported use of systematic approaches to CGM data evaluation (18-20). To date, the key CGM metrics remain as unified recommendations in three separate peer reviewed articles, yet formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice has been lacking (19).

In February 2019, the Advanced Technologies and Treatments for Diabetes (ATTD) Congress convened an international panel of individuals with diabetes and clinicians and researchers expert in CGM. Our objective was to develop evidence-based, clinical CGM targets to supplement the currently agreed-upon metrics for CGM derived times in glucose ranges (within target range, below target range, above target range) in order to provide guidance for clinicians, researchers, and individuals with diabetes in utilizing, interpreting and reporting CGM data in routine clinical care and research. Importantly, in order to make the recommendations generalizable and comprehensive, the consensus panel included individuals living with diabetes and had international representation from physicians and researchers from all geographic regions.

The panel was divided into subgroups to review literature and provide evidence-based recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations. Because long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, there is suggestive evidence from a number of recent studies, one a cross-sectional study correlating current retrospective 3-day TIR with varying degrees of diabetes retinopathy (25) and an analysis of the 7-point SMBG data from the DCCT (26) have shown correlations of time in target range (70-180 mg/dL [3.9-10.0 mmol/L]) with diabetes complication. Relationships between time in target range and A1C (25; 26) and number of severe and non-severe hypoglycemic events (27-31) have also been observed. Recommendations from each subgroup were then presented to the full panel and voted upon. This article summarizes the consensus recommendations and represents the panel members' evaluation of the issues.

Need for Metrics Beyond A1C

A1C is currently recognized as the key surrogate marker for the development of long-term diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33). While A1C reflects the average glucose over the last 2-3 months, its limitation is the lack of information about acute glycemic excursions and the acute complications of hypo- and hyperglycemia. A1C also fails to identify the magnitude and frequency of intra- and inter-day glucose variation (34; 35). Moreover, certain conditions such as anemia (36), hemoglobinopathies (37), iron deficiency (38), and pregnancy (39) can confound A1C measurements. Importantly, as reported by Beck and colleagues, the A1C test can at times fail to accurately reflect mean glucose even when none of these conditions are present (40). Despite these limitations, A1C is the only prospectively evaluated tool for assessing the risk for diabetes complications and its importance in clinical decision-making should not be undervalued. Rather, the utility of A1C is further enhanced when used in combination with CGM data.

Unlike A1C measurement, use of CGM allows for the direct observation of glycemic excursions and daily profiles, which can inform on immediate therapy decisions and/or lifestyle modifications. CGM also provides the ability to assess glucose variability (GV) and identify patterns of hypo- and hyperglycemia.

Effective use of CGM data to optimize clinical outcomes requires the user to interpret the collected data and act upon them appropriately. This requires: 1) common metrics for assessment of CGM glycemic status; 2) graphical visualization of the glucose data and CGM daily profile; and 3) clear evidence-based clinical targets.

Standardization of CGM Metrics

In February 2017, the Advanced Technologies and Treatments for Diabetes (ATTD) Congress convened an international panel of expert clinicians and researchers to define core metrics for assessing CGM data (18). (**Table 1**)

Table 1. Standardized CGM Metrics

2017 International Consensus on CGM Metrics (18)
1. Number of Days CGM Worn
2. Percentage of time CGM is active
3. Mean Glucose
4. Estimated A1c (eA1C)
5. Glycemic Variability (%CV or SD)
6. Time >250 mg/dL (>13.9 mmol/L)
7. Time >180 mg/dL (>10.0 mmol/L)
8. Time 70-180 mg/dL (3.9-10.0 mmol/L)
9. Time <70 mg/dL (<3.9 mmol/L)
10. Time <54 mg/dL (<3.0 mmol/L)
11. LBGI & HBGI (risk indices)
12. Episodes (hypoglycemia and hyperglycemia) 15 min
13. Area under the curve (AUC)
14. Time Blocks (24-h, day, night)
<i>Use of Ambulatory Glucose Profile (AGP) for CGM report</i>

CV=Coefficient of variation; SD=standard deviation; LBGI=low blood glucose index; HBGI=high blood glucose index.

The list of core CGM metrics has now been streamlined for use in clinical practice based on the expert opinion of this International Consensus Group (18). Of the 14 core metrics, the panel selected that 10 metrics that may be most useful in clinical practice (**Table 2**).

Table 2. Standardized CGM Metrics for Clinical Care

2019 Core CGM Metrics for Clinical Care (18)	
1. Number of Days CGM Worn (recommend 14 days) (41; 42)	
2. Percentage of time CGM is active (recommend 70% of data from 14 days) (41; 42).	
3. Mean Glucose	
4. Glucose Management Indicator (GMI) (43)	
5. Glycemic Variability (%CV) Target $\leq 36\%$ (44)*	
6. Time Above Range (TAR) - % of readings and time >250 mg/dL (>13.9 mmol/L)	Level 2
7. Time Above Range (TAR) - % of readings and time 181-250 mg/dL (10.1-13.9 mmol/L)	Level 1
8. Time In Range (TIR) - % of readings and time 70-180 mg/dL (3.9-10.0 mmol/L)	In Range
9. Time Below Range (TBR) - % of readings and time 54-69 mg/dL (3.0-3.8 mmol/L)	Level 1
10. Time Below Range (TBR) - % of readings and time <54 mg/dL (<3.0 mmol/L)	Level 2
<i>Use of Ambulatory Glucose Profile (AGP) for CGM report</i>	

CV=Coefficient of variation; SD=standard deviation; LBGI=low blood glucose index; HBGI=high blood glucose index.

* Some studies suggest that lower %CV targets ($<33\%$) provide additional protection against hypoglycemia for those receiving insulin or sulfonylureas: $<33\%$ (44-46)

Fundamental to accurate and meaningful interpretation of CGM is ensuring that adequate glucose data are available for evaluation. As shown in studies, $>70\%$ use of CGM over the recent 14 days correlates strongly with 3 months of mean glucose, time in ranges, and hyperglycemia metrics (41; 42). In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42). Longer CGM data collection periods may be required for individuals with more variable glycemic control (e.g., 4 weeks of data to investigate hypoglycemia exposure).

Time in Ranges

The development of blood glucose testing in 1965 provided individuals with diabetes the ability to obtain immediate information about their current glucose levels and adjust their therapy accordingly. Over the past decades, national and international medical organizations have been successful in developing, harmonizing, and disseminating standardized glycemic targets based on risk for acute and chronic complications. CGM technology greatly expands the ability to assess glycemic control throughout the day, presenting critical data to inform daily treatment decisions and quantifying time below, within, and above the established glycemic targets.

Although each of the core metrics established in the 2017 ATTD consensus conference (18) provides important information about various aspects of glycemic status, it is often impractical to assess and fully utilize many of these metrics in real-world clinical practices. To streamline data interpretation, the consensus panel identified “time in ranges” as a composite metric of glycemic control that provides more actionable information than A1C alone. The panel agreed that establishing target *percentages* of time in the various glycemic ranges with the ability to adjust the percentage cutpoints to address the specific needs of special diabetes populations (e.g., pregnancy, high-risk) would facilitate safe and effective therapeutic decision-making within the parameters of the established glycemic goals.

The composite metric includes three key CGM measurements: percentage of reading and time per day within target glucose range (TIR), time below target glucose range (TBR), and time above target glucose range (TAR) (**Table 3**). The primary goal for effective and safe glucose control is to increase the TIR while reducing the TBR. The consensus group agreed that expressing time in the various ranges can be done as the percentage (%) of CGM, average hours and minutes spent in each range or both, depending on the circumstances.

It was agreed that CGM based glycemic targets must be personalized to meet the needs of each individual with diabetes. In addition, the group reached consensus on glycemic cutpoints (a target range of 70-180 mg/dL [3.9-10.0 mmol/L] for individuals with type 1 diabetes and type 2 diabetes and 63-140 mg/dL [3.5-7.8 mmol/L] during pregnancy, along with a set of targets for the time per day [% of CGM readings or minutes/hrs]) individuals with type 1 diabetes and type 2 diabetes (**Table 3**) and women during pregnancy (**Table 4**) should strive to achieve. It should be noted that premeal and postprandial targets remain for diabetes in pregnancy (ADA Standards

of medical care-2019. Diabetes Care 2019: 42 (Suppl 1)) in addition to the new TIR targets for overall glycemia.

Table 3. Recommended cutpoints for assessment of glycemic control: Type 1 / Type 2 and Older / High-Risk Individuals

Diabetes Group	Time in Range (TIR)		Time Below Range (TBR)		Time Above Range (TAR)	
	% of readings time/day	Target Range	% of readings time /day	Below Target Level	% of readings time/ day	Above Target Level
Type 1* / Type 2	>70% >16hr, 48 min	70-180 mg/dL 3.9 -10.0 mmol/L	<4% <1 hr	<70 mg/dL <3.9 mmol/L	<25% <6 hr	>180 mg/dL >10.0 mmol/L
			<1% <15 min	<54 mg/dL <3.0 mmol/L	<5% <1 hr, 12 min	>250 mg/dL >13.9 mmol/L
Older/High-Risk Type 1 / Type 2	>50% >12 hr	70-180 mg/dL 3.9-10 mmol/L	<1% <15 min	<70 mg/dL <3.9 mmol/L	<10% <2 hr, 24 min	>250 mg/dL >13.9 mmol/L
<i>Each incremental 5% increase in TIR is associated with clinically significant benefits for Type 1 / Type 2 (25; 26)</i>						

* For age <25 yr., if the A1C goal is 7.5% then set TIR target to approximately 60%. (See “Clinical Applications of Times in Range” in the text for additional information regarding target goal setting in pediatric management)

Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy

Diabetes Group	Time in Range (TIR)		Time Below Range (TBR)		Time Above Range (TAR)	
	% of readings time/day	Target Range	% of readings time /day	Below Target Level	% of readings time/ day	Above Target Level
Pregnancy Type 1 §	>70% >16 hr, 48 min	63-140 mg/dL† 3.5-7.8 mmol/L†	<4% <1 hr	<63 mg/dL† <3.5 mmol/L†	<25% <6 hr	>140 mg/dL >7.8 mmol/L
			<1% <15 min	<54 mg/dL <3.0 mmol/L		
Pregnancy § Type 2 / GDM	see Pregnancy section	63-140 mg/dL† 3.5-7.8 mmol/L†	see Pregnancy section	<63 mg/dL† <3.5 mmol/L† <54 mg/dL <3.0 mmol/L	see Pregnancy section	>140 mg/dL >7.8 mmol/L
<i>Each incremental 5% increase in TIR is associated with clinically significant benefits for Pregnancy Type 1 (47; 48)</i>						

† Glucose levels are physiologically lower during pregnancy


§ Percentages of time in range are based on limited evidence. More research is needed.

Although the composite metric includes TIR, TBR and TAR, achieving the TBR *and* TIR goals would result in reduced time spent above range and thereby improve glycemic control. However, some clinicians may choose to target the reduction of the high glucose values and minimize hypoglycemia, thereby arriving at more time in the target range. In both approaches, the first priority is to reduce TBR to target levels and then address TIR or TAR targets.

Note that for people with type 1 diabetes, the targets are informed by the ability to reach the targets with hybrid closed-loop therapy (11), the first example of which is now commercially available, with several more systems in final stages of testing. Importantly, recent studies have shown the potential of reaching these targets with CGM in individuals using multiple daily injections (MDI) (6). In type 2 diabetes, there is generally less glycemic variability and hypoglycemia than in type 1 diabetes (46). Thus, people with type 2 diabetes can often achieve more time in target range while minimizing hypoglycemia (4). As demonstrated by Beck et al., individuals with type 2 diabetes increased their TIR by 10.3% (from 55.6% to 61.3%) after 24 weeks of CGM use with slight reductions in TBR (4). Most recently, the beneficial effects of new medications, such as sodium glucose cotransporter-2 (SGLT-2) agents have helped individuals with type 1 diabetes increase TIR (49-51). Targets for type 1 diabetes and type 2 diabetes were close enough to combine them into one set of targets, outside of pregnancy.

Another way to visualize the CGM-derived targets for the four categories of diabetes is shown in **Figure 1** which displays and compares the targets for time in range (TIR - green), time below range (TBR - 2 categories in light and dark red) and time above range (TAR -2 categories in yellow and orange). It becomes clear at a glance that there are different expectations for the various time in ranges relating to safety concerns and efficacy based on currently available therapies and medical practice.

Figure 1. International consensus on time in range: CGM-based targets for different types of diabetes



Clinical Validity of Measures

To fundamentally change clinical care with use of the new metrics, it would be important to demonstrate that the metrics relate to and predict clinical outcomes. In this regard, longer-term studies relating to time spent within specific CGM glyceic ranges, diabetes complications, and other outcomes are required. However, there is evidence from a number of recent studies that have shown correlations of TIR (70-180 mg/dL [3.9-10.0 mmol/L]) with diabetes complications (52; 53) as well as a relationship between TIR and A1C (25; 26). Although there is no evidence regarding time in range for older and/or high-risk individuals, numerous studies have shown the elevated risk for hypoglycemia in these populations (54-59). We have lowered the TIR target from >70% to >50% and reduced TBR to <1% at <70 mg/dL (<3.9 mmol/L) to place greater emphasis on reducing hypoglycemia with less emphasis on maintaining target glucose levels (Table 3).

Type 1 Diabetes and Type 2 Diabetes

Association with Complications

Associations between TIR and progression of both diabetic retinopathy (DR) and development of microalbuminuria were reported by Beck and colleagues, using the Diabetes Control and Complications Trial (DCCT) data set (7-point blood glucose profiles) to validate the use of TIR as an outcome measure for clinical trials (53). Their analysis showed that the hazard rate for retinopathy progression increased by 64% for each 10% reduction in TIR. The hazard rate for microalbuminuria development increased by 40% for 10% reduction in TIR. A post-hoc analysis of the same DCCT data set showed a link between glucose of <70 mg/dL (<3.9 mmol/L) and <54 mg/dL (<3.0 mmol/L) and an increased risk for severe hypoglycemia (60).

Similar associations between DR and TIR were reported in a recent study by Lu and colleague in which 3,262 individuals with type 2 diabetes were evaluated for DR, which was graded as: non-DR; mild nonproliferative DR (NPDR); moderate NPDR; or vision-threatening DR (VTDR) (52). Results showed that individuals with more advanced DR spent significantly less time within target (70-180 mg/dL [3.9-10.0 mmol/L]) and that prevalence of DR decreased with increasing TIR.

Relationship Between TIR and A1C

Analyses were conducted utilizing datasets from four randomized trials encompassing 545 adults with type 1 diabetes who had central-laboratory measurements of A1C (25). TIR (70-180 mg/dL [3.9-10.0 mmol/L]) of 70% and 50% strongly corresponded with an A1C of approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively. An increase in TIR of 10% (2.4 hours per day) corresponded to a decrease in A1C of approximately 0.5% (5.0 mmol/mol); similar associations were seen in an analysis of 18 RCTs by Vigersky et al. that included over 2,500 individuals with type 1 diabetes and type 2 diabetes over a wide range of ages and A1C levels (26). (**Table 4**)

Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies

Beck et al. (n=545 type 1 diabetes participants) (25)			Vigersky et al. (n=1,137 type 1/type 2 participants) (26)	
TIR 70-180 mg/dL (3.9-10.0 mmol/L)	A1C % (mmol/mol)	95% CI for predicted values	TIR 70-180 mg/dL (3.9-10.0 mmol/L)	A1C % (mmol/mol)
20%	9.4 (79)	(8.0, 10.7)	20%	10.6 (92)
30%	8.9 (74)	(7.6, 10.2)	30%	9.8 (84)
40%	8.4 (68)	(7.1, 9.7)	40%	9.0 (75)
50%	7.9 (63)	(6.6, 9.2)	50%	8.3 (67)
60%	7.4 (57)	(6.1, 8.8)	60%	7.5 (59)
70%	7.0 (53)	(5.6, 8.3)	70%	6.7 (50)
80%	6.5 (48)	(5.2, 7.8)	80%	5.9 (42)
90%	6.0 (42)	(4.7, 7.3)	90%	5.1 (32)
Every 10% increase in TIR = ~0.5% (5.5 mmol/mol) A1C reduction			Every 10% increase in TIR = ~0.8% (8.7 mmol/mol) A1C reduction	

*The difference between findings from the two studies likely stems from differences in number of studies analyzed and subjects included (RCTs with type 1 vs. RCTs with type 1/type 2 with CGM and SMBG).

Pregnancy

During pregnancy, the ambition is to safely increase TIR as quickly as possible, while reducing TAR and glycemic variability. The first longitudinal CGM data demonstrated a 13-percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61). The TBR < 50 mg/dL reduced from 6% to 4%, although the higher TBR <70 mg/dL was high (13-15%) using older generation sensors. With improved sensor accuracy, recent type 1 diabetes pregnancy studies report a lower threshold of <63 mg/dL (<3.5 mmol/L) for TBR and ≥63 mg/dL (≥3.5 mmol/L) for TIR (47; 48). Data from Sweden, and the CONCEPTT control group, report 50% TIR in the first trimester, improving to 60% TIR in the third trimester, reflecting contemporary antenatal care. Of note, these data confirm that the TBR <63 mg/dL (<3.5 mmol/L) recommendation of <4% is safely achievable, especially after the first trimester. Furthermore, 33% of women achieved the recommendation of 70% TIR 63-140 mg/dL (3.5-7.8 mmol/L) in the final (>34) weeks of pregnancy. Preliminary data suggest that closed-loop may allow pregnant women to safely achieve 70% TIR, at an earlier (>24 weeks) gestation (62; 63).

Law et al analyzed data from two early CGM trials (64; 65) describing the associations between CGM measures and risk of large for gestational age (LGA) infants. Taken together, the Swedish and CONCEPTT data confirm that a 5-7% higher TIR during the second and third trimesters is associated with decreased risk of LGA and neonatal outcomes, including macrosomia, shoulder dystocia, neonatal hypoglycemia and NICU admissions. More data are needed to define the clinical CGM targets for pregnant women with type 2 diabetes, who spend one third less time hyperglycemic than women with type 1 diabetes, and achieve TIR of 90% (61). Because of the lack of evidence on CGM targets for women with GDM or type 2 diabetes in pregnancy, percentages of time spent in range, below range, and above range have not been included in this report. Recent data suggest that even more stringent targets (66) and greater attention to overnight glucose profiles may be required to normalize outcomes in pregnant women with gestational diabetes (67).

Older and/or High-Risk Individuals with Diabetes


Older and/or high-risk individuals with diabetes are at notably higher risk for severe hypoglycemia due to age, duration of diabetes, duration of insulin therapy, and greater prevalence of hypoglycemia unawareness (54-58). The increased risk of severe hypoglycemia is compounded by cognitive and physical impairments and other co-morbidities (56; 59). High-risk individuals include those with a higher risk of complications, comorbid conditions (e.g., cognitive deficits, renal disease, joint disease, osteoporosis, fracture, and/or cardiovascular disease), and often require assisted care, which can complicate treatment regimens (59). Therefore, when setting glycemic for high-risk and/or elderly people, it is important to individualize and be conservative, with a strong focus on reducing the percentage of time spent <70 mg/dL (<3.9 mmol/L) and preventing excessive hyperglycemia.

Standardization of CGM Data Presentation

As noted above, in 2013, a panel of clinicians with expertise in CGM published recommendations for use of the Ambulatory Glucose Profile (AGP) as a template for data presentation and visualization. Originally created by Mazze et. al. (68), the standardized AGP report was further developed by the International Diabetes Center and now incorporates all the core CGM metrics and targets along with a 14-day composite glucose profile as an integral

component of clinical decision making (24). This recommendation was later endorsed at the aforementioned international consensus conference on CGM metrics (18) and is referenced as an example in the American Diabetes Association (ADA) 2019 Standards of Care (16) and in an update to the American Association of Clinical Endocrinologists (AACE) consensus on use of CGM (69). The AGP report, in slightly modified formats, has been adopted by most of the CGM device manufacturers in their download software. An example of the AGP report, updated to incorporate targets, is presented in **Figure 2**. In the AGP report, glucose ranges are defined as “Very High” (Level 2), “High” (Level 1), “Low” (Level 1) and “Very Low” (Level 2). A “mmol/L” version is provided in **Supplemental Figure 1**.

Figure 2. Ambulatory Glucose Profile



There is a general consensus that a useful CGM report is one that can be understood by clinician and people with diabetes. While there may be some terms (e.g., glucose variability) that are less familiar for many people with diabetes to understand, the value of a single-page report that the daily medical team can review and file in the electronic medical record and can be used as a shared decision-making tool with people with diabetes was considered to be of value (70-73). More detailed reports (e.g., adjustable data ranges, detailed daily reports) should remain available for individualized review by or with people with diabetes.

Clinical Application of Time in Ranges

Despite its demonstrated value, clinical utilization of CGM data has remained suboptimal. Although time constraints and reimbursement issues are clearly obstacles, clinician inexperience in data interpretation and lack of standardization software for visualization of CGM data have also played a role (74). The proposed standardized report enables clinicians to readily identify important metrics such as the percentage of time spent within, below and above each individual's target range, allowing for greater personalization of therapy through shared decision making.

Using the standardized report the clinician can also address glucose variability (e.g., %CV metric) (75) or use glucose management indicator (GMI) metric (43) to discuss the possible discrepancies noted in glucose exposure derived from CGM data versus the individual's laboratory-measured A1C (40; 76). With appropriate educational materials, time and experience, clinicians will develop a systematic approach to CGM data analysis and the most effective ways to discuss the data with patients in person or remotely.

Goal Setting

Numerous studies have demonstrated the clinical benefits of early achievement of near-normal glycemic control in individuals with type 1 diabetes and type 2 diabetes (77-83). However, when advising people with diabetes, goal-setting must be collaborative and take into account the individual needs/capabilities of each patient and start with the goals that are most achievable. An early study by DeWalt and colleagues found that setting small, achievable goals not only enhances people's ability to cope with their diabetes, but that people with diabetes who set and achieved their goals often initiated additional behavioral changes on their own (84). One approach to consider is the *S.M.A.R.T. Goal* (Specific, Measurable, Achievable, Relevant, Time bound) intervention, which is directly applicable to setting targets for times in ranges. First described by Lawlor and Hornyak in 2012 (85), this approach incorporates four key components of behavioral change relevant to goal setting: 1) the goal is specific and defines exactly what is to be achieved; 2) the goal is measurable and there is tangible evidence when it has been achieved; 3) the goal is achievable but stretches the patient slightly so that he/she feels challenged; and 4) the goal should be attainable over a short period of time.

Effective goals should utilize CGM data to identify specific instances for the patient to take measurable action to prevent hypoglycemia. Although analysis of the AGP reports provides

an opportunity for meaningful discussion, individuals should be counseled to look at patterns throughout the day to see when low glucose events are occurring and make adjustments in their therapy to reduce these events.

When applying the CGM metrics in clinical practice, it may be more meaningful and motivating to communicate to people with diabetes the importance of working to reduce the time spent <70 mg/dL (<3.9 mmol/L) to less than one hour per day and less than 15 minutes per day <54 mg/dL (<3.0 mmol/L) rather than using $<4\%$ and $<1\%$ respectively, as the goal. However, as discussed earlier, targets must be personalized to meet the needs and capabilities of each person, focusing on small steps and small successes. Individuals with diabetes should work with their physician and/or educator to develop a SMART goal to reduce time below range.

Individualized goals are particularly important for pediatric and young adult populations. The International Society for Pediatric Diabetes (ISPAD) recommends that targets for individuals ≤ 25 years aim for the lowest achievable A1C without undue exposure to severe hypoglycemia balances with quality of life and burden of care (86). An A1C target of 7.0% (53 mmol/mol) can be used in children, adolescents and adults ≤ 25 years who have access to comprehensive care (86). However, a higher A1C goal (e.g., $<7.5\%$ [<58 mmol/mol]) may be more appropriate in the following situations: inability to articulate hypoglycemia symptoms; hypoglycemia; hypoglycemia unawareness; history of severe hypoglycemia, lack of access to analog insulins and/or advanced insulin delivery technology, inability to regularly check glucose (86). This would equate to a TIR target of $\sim 60\%$ (**Table 4**).

The consensus group recognized that achieving the targets for the various time in ranges is aspirational in some situations and many individuals will require ongoing support, both educational and technological, from their healthcare team. Importantly, as demonstrated by Beck et al. (25), Vigersky et al. (26) and Feig et al. (47), even small, incremental improvements yield significant glycemic benefits. Therefore, when advising individuals with diabetes (particularly children, adolescents, high-risk) about their glycemic goals, it is important to take a step-wise approach, emphasizing that what may appear to be small, incremental successes (e.g. 5% increase in TIR) are, in fact, clinically significant in improving their glycemic control (25; 26; 47). However, when counseling women planning pregnancy and pregnant women, greater emphasis should be placed on getting to goal as soon as possible (47; 48).

Conclusions

Use of CGM continues to expand in clinical practice. As a component of diabetes self-management, daily use of CGM provides the ability to obtain immediate feedback on current glucose levels, direction and rate of change in glucose levels. This information allows people with diabetes to optimize dietary intake and exercise, make informed therapy decisions regarding meal-time and correction of insulin dosing and, importantly, react immediately and appropriately to mitigate or prevent acute glycemic events (87-89). Retrospective analysis of CGM data, utilizing standardized data management tools such as the AGP, enables clinicians and people with diabetes to work collaboratively in identifying problem areas and then set achievable goals (71-73). We conclude that, in clinical practice, *time in ranges* (within target range, below range, above range) are both appropriate and useful as clinical targets and outcome measurements that complement A1C for a wide range of people with diabetes, and that the target values specified in this paper should be considered an integral component of CGM data analysis and day-to-day treatment decision making.

Author Contributions

T.B., R.M.B., W.C., T.D., S.G., L.H. I.M.B., C.M., H.M., S.A., R.N., K.D., C.G.P. and M.P. wrote and revised the initial manuscript drafts. All authors reviewed, provided input, and approved the final manuscript. T.B. is the guarantor of this work and takes full responsibility for the integrity of the information included in the report.

Acknowledgements

The consensus group participants wish to thank Advanced Technologies and Treatments for Diabetes (ATTD) for organizing and coordinating the meeting. We also wish to thank Rachel Naveh for assistance in organizing the meeting. We would like to thank Courtney Lias from the U.S. Food and Drug Administration for her participation as an observer at the consensus conference.

Funding

Support for the CGM consensus conference and development of this manuscript was provided by the Advanced Technologies and Treatments for Diabetes (ATTD) Congress. Abbott Diabetes Care, Astra Zeneca, Dexcom Inc., Eli Lilly & Company, Insulet Corporation, Medtronic, Novo Nordisk, Roche Diabetes Care, and Sanofi provided funding to ATTD to support the consensus meeting. All consensus participants were reimbursed for travel to the ATTD conference and one night lodging; no honoraria were provided. Editorial support was provided by Christopher G. Parkin, MS, CGParkin Communications, Inc.

Financial Disclosures

Tadej Battelino - T.B. has received honoraria for participation on advisory boards for Novo Nordisk, Sanofi, Eli Lilly & Company, Boehringer, Medtronic and Bayer Health Care and as a speaker for Astra Zeneca, Eli Lilly & Company, Bayer, Novo Nordisk, Medtronic, Sanofi and Roche. TB owns stocks of DreamMed Diabetes; his institution has received research grant support and travel expenses from Abbott Diabetes Care, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz and Diamyd.

Thomas Danne - T.D. has received speaker honoraria, research support and consulting fees from Abbott Diabetes Care, Bayer, BMS, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly & Company, Medtronic, Novo Nordisk, Sanofi, and Roche Diabetes Care; he is a shareholder of DreaMed Diabetes.

Stephanie A. Amiel - S.A.A. declared no conflicts of interest.

Roy Beck - R.W.B. is an employee the Jaeb Center for Health Research, which has received grant support from Dexcom, Animas, Bigfoot, Tandem, non-financial study support from Dexcom, Abbott Diabetes Care, and Roche Diabetes Care, and consulting fees from Eli Lilly and Company and Insulet; he has no personal financial arrangements with any company.

Richard M. Bergenstal - R.M.B. has received research funding and served as a consultant and served on advisory boards for Abbott Diabetes Care, Becton-Dickinson, DexCom, Eli Lilly and Company, Glooko, Helmsley Charitable Trust, Hygieia, Johnson & Johnson, Medtronic, Merck, Novo Nordisk, Roche, Sanofi, and Senseonics; his employer, non-profit HealthPartners Institute, contracts for his services and no personal income goes to R.M.B.

Torben Biester - T.B. declared no conflicts of interest.

Emanuele Bosi - E.B. received honoraria for participation on advisory boards and speaker bureaus from Abbott Diabetes Care, Astra Zeneca, Medtronic, Novartis, Roche, and Sanofi.

Bruce Buckingham - B.B. declared no conflicts of interest.

William Cefalu - W.C. declared no conflicts of interest.

Kelly L. Close - K.L.C. is an employee of Close Concerns and diaTribe, which receive funding CGM manufacturers, including Medtronic, Dexcom and Abbott Diabetes Care.

Claudio Cobelli - C.C. declared no conflicts of interest.

Eyal Dassau - E.D. has received consulting fees and honoraria for participation on advisory boards for Animas, Insulet, Eli Lilly and Company and research support from Dexcom, Insulet, Animas, Xeris.

J. Hans DeVries - J.H.DV. has received speaker honoraria and research support and has consulted for Abbott Diabetes Care, Dexcom, Medtronic, MSD, Novo Nordisk, Sanofi, Roche, Senseonics and Zealand.

Kim Donaghue - K.D. declared no conflicts of interest.

Klemen Dove - K.D. declared no conflicts of interest.

Francis J. Doyle III - F.J.DIII. has received consulting fees from ModeAGC and research support from Dexcom, Insulet, Animas, and Xeris.

Satish Garg - S.G. has received consulting fees and honoraria for participation on advisory boards for Medtronic, Roche Diabetes Care, Merck, Lexicon, Novo-Nordisk, Sanofi, Mannkind, Senseonics, Zealand, and Eli Lilly and Company and research grants from Eli Lilly and Company, Novo-Nordisk, Merck, Lexicon, Medtronic, Dario, NCI, T1D Exchange, NIDDK, JDRF, Animas, Dexcom, and Sanofi.

George Grunberger - G.G. has received consulting fees from Novo Nordisk and Medtronic and honoraria for participation on speaker bureaus from Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, and Sanofi.

Simon Heller - S.H. declared no conflicts of interest.

Lutz Heinemann - L.H. declared no conflicts of interest.

Irl B. Hirsch - L.B.H. declared no conflicts of interest.

Roman Hovorka - R.H. reports having received speaker honoraria from Eli Lilly and Company Lilly, Novo Nordisk and Astra Zeneca, serving on advisory panel for Eli Lilly and Company and Novo Nordisk, and receiving license fees from BBraun and Medtronic.

Weiping Jia - W.J. declared no conflicts of interest.

Olga Kordonouri - O.K. declared no conflicts of interest.

Boris Kovatchev - B.K. declared no conflicts of interest.

Aaron Kowalski - A.K. declared no conflicts of interest.

Brian Levine - B.L. is an employee of Close Concerns and diaTribe, which receive funding CGM manufacturers, including Medtronic, Dexcom and Abbott Diabetes Care.

Aleksander Mayorov - A.M. declared no conflicts of interest.

Chantal Mathieu - C. M. serves or has served on the advisory panel or speaker's bureau for Novo Nordisk, Sanofi, Merck Sharp and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Hanmi Pharmaceuticals, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Dianax and UCB. Financial compensation for these activities has been received by KU Leuven.

Helen R. Murphy - H.R.M. received honoraria from participation on advisory boards for Medtronic and research support from Dexcom, Medtronic, Abbott Diabetes Care, and Johnson & Johnson.

Revital Nimri - R.N. declared no conflicts of interest.

Kirsten Nørgaard - K.N. owns shares in Novo Nordisk and has received consulting fees from Medtronic, Abbott Diabetes Care and Novo Nordisk, speaker honoraria from Medtronic, Roche Diabetes Care, Rubin Medical, Sanofi, Novo Nordisk, Zealand Pharma and Bayer, and research support from Novo Nordisk, Zealand Pharma, Medtronic, and Roche Diabetes Care.

Christopher G. Parkin - C.G.P. has received consulting fees from Dexcom, Diasome, Onduo, Proteus, Roche Diabetes Care, and Senseonics.

Eric Renard - E.R. has received consulting fees from A. Menarini Diagnostics, Abbott Diabetes Care, Becton-Dickinson, Cellnovo, Dexcom Inc., Eli Lilly and Company, Insulet Inc., Johnson & Johnson, Medtronic, Novo-Nordisk, Roche, Sanofi and research support from Abbott Diabetes Care, Dexcom, Insulet, and Roche.

David Rodbard - D.R. has received consulting fees from Eli Lilly and Company and Better Therapeutics.

Banshi Saboo - B.S. declared no conflicts of interest

Desmond Schatz - D.S. declared no conflicts of interest.

Keaton Stoner - K.S. declared no conflicts of interest.

Tatsuiko Urakami - T.U. declared no conflicts of interest.

Stuart A. Weinzimer - S.A.W. has received consulting fees from Insulet.

Moshe Phillip - M.P. is a member of the Advisory Board of AstraZeneca, Sanofi, Medtronic, Eli Lilly, Novo Nordisk, Insulet and is a consultant to RSP Systems A/S, Qulab Medical, and Pfizer. The Institute headed by MP received research support from Medtronic, Novo Nordisk, Eli Lilly, Dexcom, Sanofi, Insulet, OPKO, DreaMed Diabetes, Bristol-Myers Squibb, and Merck. MP is a stock/shareholder of DreaMed Diabetes, NG Solutions and Nutriteen Professionals and reports two patent applications.

References

1. Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. *JAMA* 2017;317(4):379-387
2. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. *Diabetes Care* 2017;40(4):538-545.
3. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. *JAMA* 2017; 317:371-378.
4. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. *Ann Intern Med* 2017;167:365-374.
5. Polonsky WH, Hessler D, Ruedy KJ, Beck RW, for the DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. *Diabetes Care* 2017; 40:736-741.
6. Šoupal J, Petruželková L, Flekač M, et al. Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study. *Diabetes Technol Ther*. 2016;18(9):532-538.
7. van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. *Lancet Diabetes Endocrinol*. 2016;4(11):893-902.
8. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. *Lancet* 2016;388:2254-2263.
9. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. *Diabetes Ther* 2017;8(1):55-73.
10. Choudhary P, Olsen BS, Conget I, et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. *Diabetes Technol Ther* 2016;18(5):288-291.
11. Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. *JAMA*. 2016;316:1407-1408.
12. Heinemann L, Guido Freckmann G, Gabriele Faber-Heinemann G, et al. Benefits of continuous glucose monitoring use in adults with type 1 diabetes and impaired hypoglycaemia awareness and/or severe hypoglycaemia treated with multiple daily insulin injections: Results of the multicentre, randomised controlled HypoDE study. *The Lancet* 2018 (In Press).
13. Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomised controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycaemia. *Diabet Med*. 2017 Dec 12. doi: 10.1111/dme.13561. [Epub ahead of print].

14. Battelino T, Nimri R, Dovc K, Phillip M, Bratina N. Prevention of Hypoglycemia with Predictive Low Glucose Insulin Suspension in Children with Type 1 Diabetes: A Randomized Controlled Trial. *Diabetes Care*. 2017;40(6):764-770.
15. Dovc K, Cargnelutti K, Sturm A, Selb J, Bratina N, Battelino T. Continuous glucose monitoring use and glucose variability in pre-school children with type 1 diabetes. *Diabetes Res Clin Pract*. 2019 Jan;147:76-80.
16. American Diabetes Association. 7. Diabetes technology. Standards of medical care-2019. *Diabetes Care* 2019; 42 (Suppl 1): S71-S80.
17. Fonseca VA, Grunberger G, Anhalt H, et al. for the Consensus Conference Writing Committee. Continuous Glucose Monitoring: A Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. *Endocr Pract*. 2016;22(8):1008-1021.
18. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of Continuous Glucose Monitoring. *Diabetes Care*. 2017;40(12):1631-1640.
19. Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming A, Heinemann L. Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations. A Joint Statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. *Diabetes Care* 2017;40:1614–1621.
20. Agiostratidou G, Anhalt H, Ball D, et al. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, the Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. *Diabetes Care* 2017; 40(12):1622-1630.
21. Sherr JL, Tauschmann M, Battelino T, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes Technologies. *Pediatr Diabetes*. 2018;19(Suppl 27):302-325.
22. Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. *Diabetes Technol Ther* 2019; 1 Feb 2019 <https://doi.org/10.1089/dia.2018.0384>.
23. Foster NC, Miller K, Dimeglio L, et al. Marked Increases in CGM Use Has Not Prevented Increases in HbA1c Levels in Participants in the T1D Exchange (T1DX) Clinic Network. *Diabetes* 2018;67(Suppl 1). <https://doi.org/10.2337/db18-1689-P>. Accessed April 1, 2019.
24. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). *Diabetes Technol Ther*. 2013;15(3):198-211.
25. Beck RW, Bergenstal RM, Cheng P, Kollman C, Carlson AL, Johnson ML, Rodbard D. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. *J Diabetes Sci Technol*. 2019 Jan 13:1932296818822496. doi: 10.1177/1932296818822496. [Epub ahead of print].
26. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. *Diabetes Technol Ther*. 2019;21(2):81-85.
27. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. *Value Health*. 2011;14(5):665-671.

28. Brod M, Rana A, Barnett AH. Impact of self-treated hypoglycaemia in type 2 diabetes: A multinational survey in patients and physicians. *Curr Med Res Opin.* 2012;28:1947-1958.
29. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. *Diabetes Care* 2013;36:1384–1395.
30. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: A joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 40 (2017), pp. 155-157.
31. Novodvorsky P, Bernjak A, Chow E, et al. Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes. *Diabetes Care* 2017;40:655–662.
32. Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. *Diabetologia* 2012;55(12):3155-3162.
33. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Sensor-augmented pump therapy for A1C reduction (Star 3) study: results from the 6-month continuation phase. *Diabetes Care.* 2011;34:2403-2405.
34. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. *J Clin Endocrinol Metab* 1994;79:1659-1662.
35. Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. *Diabetes Technol Ther* 2012.;14(11):1008-1012.
36. National Diabetes Information Clearinghouse (NDIC). Sickle cell trait and other hemoglobinopathies and diabetes: important information for providers [Internet]. Available from <http://diabetes.niddk.nih.gov/dm/pubs/hemovari-A1C/index.aspx>. Accessed January 12, 2018.
37. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. *Clin Chem* 2001;47(2):153-163.
38. Ford ES, Cowie CC, Li C, Handelsman Y, Bloomgarden ZT. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. *J Diabetes* 2011;3(1):67-73.
39. Nielsen LR, Ekblom P, Damm P, et al. HbA1c levels are significantly lower in early and late pregnancy. *Diabetes Care* 2005;27(5):1200-1201.
40. Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. *Diabetes Care* 2017;40:994-999
41. Xing D, Kollman C, Beck RW, et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring. *Diabetes Technol Ther* 2011;13:351-358.
42. Riddlesworth TD, Beck RW, Gal RL, et al. Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control. *Diabetes Technol Ther.* 2018;20(4):314-316.
43. Bergenstal RM, Beck RW, Close KL, et al. Glucose Management Indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. *Diabetes Care* 2018;41:2275–2280.

44. Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. *Diabetes Care* 2017;40:832–838.
45. Rodbard D. Hypo- and hyperglycemia in relation to the mean, standard deviation, coefficient of variation, and nature of the glucose distribution. *Diabetes Technol Ther.* 2012 Oct;14(10):868-876.
46. Rama Chandran S, Tay WL, Lye WK, et al. Beyond HbA1c: Comparing Glycemic Variability and Glycemic Indices in Predicting Hypoglycemia in Type 1 and Type 2 Diabetes. *Diabetes Technol Ther.* 2018 May;20(5):353-362.
47. Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. *Lancet.* 2017;390:2347-2359.
48. Kristensen K, Ögge LE, Sengpiel V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. *Diabetologia* 2019 <https://doi.org/10.1007/s00125-019-4850-0>. Accessed April 4, 2019.
49. Famulla S, Pieber TR, Eilbracht J, et al. Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1). *Diabetes Technol Ther.* 2017 Jan;19(1):49-60.
50. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. *Diabetes Care* 2018;41(12):2552-2559.
51. Mathieu M, Dandona P, Moshe P, et al. Glucose Variables in Type 1 Diabetes Studies with Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data from DEPICT-1 and 2. *Diabetes Care* 2019 (IN PRESS).
52. Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. *Diabetes Care.* 2018;41(11):2370-2376.
53. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. *Diabetes Care.* 2018 Oct 23. pii: dc181444. doi: 10.2337/dc18-1444. [Epub ahead of print]. <http://care.diabetesjournals.org/content/early/2018/10/17/dc18-1444.long>. Accessed November 15, 2018.
54. Weinstock RS, DuBose SN, Bergenstal RM, et al. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. *Diabetes Care* 2016;39(4):603-610.
55. Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. *Diabetes Care* 2009; 32:1513-1517.
56. Punthakee Z, Miller ME, Launer LJ, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. *Diabetes Care* 2012; 35:787-793.
57. Giorda CB, Ozzello A, Gentile S, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. *Acta Diabetol* 2015; 52:845-853.

58. Cariou B, Fontaine P, Eschwege E, et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. *Diabetes Metab* 2015; 41:116-125.
59. Abdelhafiz AH, Rodríguez-Mañas L, Morley JE, Sinclair AJ. Hypoglycemia in Older People - A Less Well Recognized Risk Factor for Frailty. *Aging Dis* 2015;6(20):156-167.
60. Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C. The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. *Diabetes Technol Ther*. 2019 Jan;21(1):1-5. doi: 10.1089/dia.2018.0362. Epub 2018 Dec 21.
61. Murphy HR, Rayman G, Duffield K, et al. Changes in the glycemic profiles of women with type 1 and type 2 diabetes during pregnancy. *Diabetes Care*. 2007;30(11):2785-2791.
62. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. *N Engl J Med*. 2016;375(7):644-654.
63. Stewart ZA, Wilinska ME, Hartnell S, et al. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. *Diabetes Care* 2018;41(7):1391-1399.
64. Murphy HR, Rayman G, Lewis K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. *BMJ* 2008;337:a1680.
65. Secher AL, Ringholm L, Andersen HU, Damm P, Mathiesen ER. The Effect of Real-Time Continuous Glucose Monitoring in Pregnant Women With Diabetes: A randomized controlled trial. *Diabetes Care* 2013;36(7):1877-1883.
66. Paramasivam SS, Chinna K, Singh AKK, et al. Continuous glucose monitoring results in lower HbA1c in Malaysian women with insulin-treated gestational diabetes: a randomized controlled trial. *Diabet Med* 2018;35(8):1118-1129.
67. Law GR, Alnaji A, Alrefaii L, et al. Suboptimal Nocturnal Glucose Control Is Associated With Large for Gestational Age in Treated Gestational Diabetes Mellitus. *Diabetes Care* 2019;42(5):810-815.
68. Mazze RS, Lucido D, Langer O, Hartmann K, Rodbard D. Ambulatory glucose profile: representation of verified self-monitored blood glucose data. *Diabetes Care*. 1987;10(1):111-117.
69. Fonseca V, Grunberger G. Standard Glucose Reporting: Follow-up to the February 2016 AACE CGM Consensus Conference. *Endocrine Practice* 2017;23(5):629-632
70. Mullen DM, Bergenstal R, Criego A, Arnold KC, Goland R, Richter S. Time Savings Using a Standardized Glucose Reporting System and Ambulatory Glucose Profile. *J Diabetes Sci Technol*. 2018;12(3):614-621.
71. Carlson AL, Mullen DM, Bergenstal RM. Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes. *Diabetes Technol Ther* 2017;19(S2):S4-S1.
72. Hirsch IB, Verderese CA. Professional flash continuous glucose monitoring with ambulatory glucose profile reporting to supplement A1C: rationale and practical implementation. *Endocr Pract* 2017;23:1333-1344.
73. Kruger DF, Edelman SV, Hinnen DA, Parkin CG. Reference guide for integrating continuous glucose monitoring into clinical practice. *Diabetes Educ*. 2019 Feb;45(suppl 1):3S-20S.
74. Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities. *Diabetes Technol Ther* 2016;18(Suppl 2):S2-3-S2-13.

75. Rodbard D. Glucose Variability: A Review of Clinical Applications and Research Developments. *Diabetes Technol Ther.* 2018;20(S2):S25-S215.
76. Cohen RM, Franco RS, Smith EP, Higgins JM. When HbA1c and Blood Glucose Do Not Match: How Much Is Determined by Race, by Genetics, by Differences in Mean Red Blood Cell Age? *J Clin Endocrinol Metab.* 2019;104(3):707-710.
77. Svensson E, Baggesen LM, Johnsen SP, et al. Early Glycemic Control and Magnitude of HbA1c Reduction Predict Cardiovascular Events and Mortality: Population-Based Cohort Study of 24,752 Metformin Initiator. *Diabetes Care* 2017;40(6):800-807.
78. Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating “clinical inertia” from appropriate care. *J Gen Intern Med.* 2007;22:1648–1655.
79. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329, 977-986
80. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352(9131):837-853.
81. Holman RR, Paul SK, Bethel A, Matthews DR, Neil HAW. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. *N Engl J Med* 2008; 359:1577-1589.
82. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet.* 2010;376(9739):419-430.
83. Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. *N Engl J Med.* 2015;372:2197-2206.
84. DeWalt DA, Davis TC, Wallace AS, et al. Goal setting in diabetes self-management: Taking the baby steps to success. *Patient Educ Couns* 2009;77(2):218-223.
85. Lawlor KB, Hornyak MJ. SMART goals: how the application of SMART goals can contribute to achievement of student learning outcomes. *Developments in Business Simulation and Experiential Learning* 2012;39:259-267
86. DiMeglio LA, Acerini C, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. *Pediatr Diabetes.* 2018;19(Suppl 270):105-114.
87. Aleppo G, Laffel LM, Ahmann AJ, et al. Practical approach to using trend arrows on the Dexcom G5 CGM system for the management of adults with diabetes. *J Endocr Soc.* 2017;20;1(12):1445-1460.
88. Laffel LM, Aleppo G, Buckingham BA, et al. A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes. *J Endocr Soc.* 2017;1(12):1461-1476.
89. Kudva YC, Ahmann AJ, Bergenstal RM, et al. Approach to using trend arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in adults. *J Endocr Soc* 2018;14;2(12):1320-1337.